secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001104659-26-016792
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics licenses SYN-020 to Rasayana for $300K upfront, up to $38M milestones
--------------------------------------------------------------------------------

- Upfront payment of $300,000 received; eligible for $16M development/regulatory and $22M sales milestones.
- Tiered single-digit royalties on net sales of SYN-020; Rasayana assumes all development and commercialization costs.
- SYN-020 is an oral IAP enzyme with Phase 1 safety data; Rasayana plans Phase 2 testing.
- Theriva to focus on lead pancreatic cancer program VCN-01 following out-license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/0001104659-26-016792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/tm266493d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-016792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer